FinnGen is a research project in genomics and personalized medicine. It is large public-private partnership that has collected and analysed genome and health data from 500,000 Finnish biobank donors to understand the genetic basis of diseases. FinnGen is now expanding into understanding the progression and biological mechanisms of diseases. FinnGen provides a world-class resource for further breakthroughs in disease prevention, diagnosis, and treatment and a outlook into our genetic make-up.
The FinnGen study utilises samples collected by a nationwide network of Finnish biobanks. The study is based on combining genome information with digital health care data from national health registries.
The genome data produced during the project will be owned by the Finnish biobanks, and remain available for researcher purposes. The medical breakthroughs that arise from the project will eventually benefit health care systems and patients globally.
The collaborative nature of the FinnGen research project is exceptional compared to many other studies. The study involves all the same actors as drug development. With this open cooperation, we hope to speed up the emergence of new innovations.
Data freeze 13 results and summary statistics now available!
Results can be browsed online using the FinnGen web browser and the summary statistics downloaded
This data freeze consists of >500,000 individuals, more than 21.3 M variants and >2,750 health endpoints. To get more information about how to access the results and summary statistics, please follow this link:
New accessible and engaging FinnGen communication resource available!
Scroll through the website to learn about the FinnGen project, its goals, processes and its impact in Finland and around the world.
Can you imagine what genetic diversity looks like in large populations or visualise where genes are located on chromosomes in relation to each other? We teamed up with Aalto University to produce a resource that uses data visualisation to tell the FinnGen story to a wider audience.